Calidi Biotherapeutics to Showcase Innovative Cancer Immunotherapy Platform at Investor Webinar
Calidi Biotherapeutics will host an investor webinar highlighting its stem cell-based delivery platforms for oncolytic virus therapies, featuring updates on promising cancer treatment programs designed to enhance immune system response.
Calidi Biotherapeutics will host a live investor webinar on April 24, 2025, to provide insights into its innovative cancer immunotherapy pipeline. Led by new Chief Medical Officer Dr. Guy Travis Clifton, the event will spotlight the company's advanced stem cell-based delivery platforms targeting various cancer indications.
The webinar will focus on three key programs: CLD-201, an FDA-cleared therapy advancing toward solid tumor trials; CLD-400, targeting metastatic and lung cancer; and CLD-101, aimed at high-grade gliomas. These platforms represent a potential breakthrough in cancer treatment by utilizing allogeneic stem cells to carry oncolytic viruses.
Calidi's approach represents a significant advancement in cancer therapy, offering a dual strategy that could potentially treat and prevent metastatic disease. The company's off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and enhance the efficacy of oncolytic viruses while improving patient safety.
By leveraging proprietary technology that empowers the immune system, Calidi Biotherapeutics is developing preclinical therapies that could dramatically improve cancer treatment outcomes. The upcoming webinar provides investors and healthcare professionals an opportunity to learn about the company's cutting-edge research and potential therapeutic innovations.
Following the presentation, a live question-and-answer session will allow participants to gain deeper insights into the company's scientific approach and future development strategies.